Ongoing Clinical Trials for Stevens-Johnson Syndrome
This article provides information about ongoing clinical trials investigating new treatments for Stevens-Johnson Syndrome, a serious skin condition that causes painful blisters and widespread skin detachment. Currently, there is 1 clinical trial underway testing whether filgrastim can help stop the progression of this severe skin reaction when added to standard treatment.
Clinical trial locations
Study on Filgrastim for Patients with Severe Bullous Drug Eruptions: Lyell and Stevens-Johnson Syndromes
This trial is investigating whether adding filgrastim to standard treatment can help patients with severe skin reactions, including Stevens-Johnson syndrome and the related condition Lyell syndrome (also known as Toxic Epidermal Necrolysis). These are serious conditions that cause painful skin rashes and blisters, and in severe cases can lead to large areas of skin peeling off.
Who can participate:
- Patients must be at least 6 years old
- Patients must have been diagnosed with Stevens-Johnson syndrome or Lyell syndrome
- The condition must have started less than 7 days ago, with worsening of the skin detachment or rash within the last 48 hours
- Patients or their guardians must be able to understand the trial’s purpose and provide written consent
- Patients must be registered with a social security scheme or similar coverage
- Women who can become pregnant must have a negative pregnancy test before joining
Who cannot participate:
- Patients who have previously had Lyell syndrome or Stevens-Johnson syndrome
- Patients outside the specified age range
- Patients who are part of vulnerable populations that might be at higher risk
What the trial involves:
The study divides participants into two groups. One group receives the standard treatment for these skin conditions along with filgrastim, while the other group receives standard treatment with a placebo (an inactive substance). The trial lasts for five days of active treatment, with the main goal of determining whether the skin condition stops getting worse by day 5.
Filgrastim is given as an injection or infusion directly into the body through a needle. This medication works by stimulating the production of white blood cells, which may help the body fight infections and recover from severe skin damage. Researchers will monitor whether filgrastim can halt the progression of skin detachment more effectively than standard treatment alone.
What researchers are measuring:
The primary focus is comparing how many patients in each group experience a halt in disease progression by day 5. The study also examines how quickly the skin heals, overall health outcomes at 30 days and one year, and any side effects experienced during the study. Researchers will also track the use of additional treatments like corticosteroids and evaluate patients’ quality of life and potential long-term effects up to one year after treatment.
Summary
Currently, there is one clinical trial underway for Stevens-Johnson Syndrome, located in France. This trial focuses specifically on testing filgrastim, a medication that stimulates white blood cell production, as a potential addition to standard treatment. The trial aims to determine whether this approach can more effectively halt the progression of severe skin detachment compared to standard treatment alone.
For patients with Stevens-Johnson syndrome who meet the eligibility criteria and are located in France, this trial represents an opportunity to access a potentially beneficial treatment while contributing to medical knowledge about this serious condition. The trial includes comprehensive monitoring over a full year to assess both immediate and long-term outcomes.